By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intrexon Corporation 

20374 Seneca Meadows Parkway

Germantown  Maryland  20876  U.S.A.
Phone: 301-556-9900 Fax: 301-556-9901


Through the engineering of biology, Intrexon is helping to address some of the world’s most pressing challenges and is working with industry and government leaders to realize a better, healthier planet. Today our platform is delivering new therapies in health, supplying unique solutions to address global energy demand, developing unparalleled features and productivity advancements in food, creating innovative applications for consumers, and helping to restore and protect the environment.

To execute on its mission, Intrexon has integrated a suite of technologies and expertise across a number of cellular systems to drive development and commercialization of bio-based solutions. Our solutions include: Friendly™ Aedes mosquitoes genetically engineered to suppress the invasive Aedes aegypti mosquito; Arctic® apples that will not brown when bitten, sliced, or bruised; a clinically validated transcriptional gene switch to precisely control production of biotherapeutics; bovine reproductive technologies driving genetic gain for the dairy and beef industries; genetically engineered miniature swine models to provide better predictive efficacy in evaluation of new medicines; and our AquAdvantage® salmon bringing productivity benefits to the aquaculture industry through our majority-owned subsidiary AquaBounty. Intrexon’s cutting-edge platforms have broad applicability, thus opening the door to the considerable potential of engineered biology.

Intrexon and our collaborators are building solutions to challenging issues across fields as diverse as medicine, fuel, agriculture, nutrition, personal care, chemicals, and manufacturing, forging a sustainable path forward for current and future generations. We call our approach Better DNA® and invite you to discover more at or follow us on Twitter at @Intrexon, on Facebook and LinkedIn.

Key Statistics

Ownership: Public

Web Site: Intrexon
Symbol: XON

Company News
Intrexon (XON) Announces Second Quarter and First Half 2017 Financial Results 8/10/2017 1:01:21 PM
Intrexon (XON) To Announce Second Quarter And First Half 2017 Financial Results On August 9th 8/2/2017 12:44:17 PM
Intrexon (XON) Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics And Head Of Research And Development Of Precigen 6/30/2017 6:45:49 AM
Intrexon (XON) Integrates Leading Adenoviral Gene Delivery Technology With Completion of GenVec (GNVC) Acquisition 6/16/2017 7:31:36 AM
Intrexon (XON) And Johnson Matthey Pharma Services (JMAT.L) Collaborate On Fermentative Production Of Peptide-Based Active Pharmaceutical Ingredients 6/13/2017 7:25:32 AM
Intrexon (XON) Appoints Dr. Mark Carnegie-Brown As CEO Of Oxitec 5/19/2017 6:35:51 AM
Intrexon (XON) Announces First Quarter 2017 Financial Results 5/11/2017 9:02:42 AM
Intrexon (XON) And Darling To Build Commercial-Scale Production Of Insect-Based Advanced Feed Ingredients 5/10/2017 9:07:31 AM
Huvepharma To Utilize Intrexon (XON)'s Proprietary Fungal Expression Platform To Produce Key Animal Feed Enzyme 5/9/2017 11:20:14 AM
Intrexon (XON) To Announce First Quarter 2017 Financial Results On May 10th 5/3/2017 11:03:01 AM